Moleculin Biotech
MBRX
MBRX
26 hedge funds and large institutions have $3.16M invested in Moleculin Biotech in 2022 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 4 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more ownership
Funds ownership: →
27% less capital invested
Capital invested by funds: $4.32M → $3.16M (-$1.16M)
Holders
26
Holding in Top 10
–
Calls
–
Puts
–
Top Buyers
| 1 | +$21K | |
| 2 | +$14K | |
| 3 | +$12K | |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$9.26K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$5.71K |
Top Sellers
| 1 | -$46K | |
| 2 | -$17K | |
| 3 | -$3.83K | |
| 4 |
BlackRock
New York
|
-$2.28K |
| 5 |
CAPTRUST Financial Advisors
Raleigh,
North Carolina
|
-$1K |